Bootstrapping a Portuguese WordNet from Galician, Spanish and English wordnets

Series: Lecture notes in computer science, ISSN 0302-9743, vol. 8854In this article we exploit the possibility on bootstrapping an European Portuguese WordNet from the English, Spanish and Galician wordnets using Probabilistic Translation Dictionaries automatically created from parallel corpora. The process generated a total of 56~770 synsets and 97~058 variants. An evaluation of the results using the Brazilian OpenWordNet-PT as a gold standard resulted on a precision varying from 53\% to 75\% percent, depending on the cut-line. The results were satisfying and comparable to similar experiments using the WN-Toolkit.PEst-OE/EEI/UI0752/2014, TIN2012-38584-C06-01, TIN2012-38584-C06-0

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

This study was supported by the Ministerio de Economía y Competitividad, Grant n. SAF2015-67633-R ,and PI16/00420 which are part of Plan Nacional de I+D+I and are co-financed by the European Regional Development Fund (FEDER-“Una manera de hacer Europa”) and the CERCA program from Generalitat Catalunya. European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement n. 306240; Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR1009, and Departament de Salut (SLT002-16-00350), Instituto de Salud Carlos III (ISCIII) International Cancer Genome Consortium for Chronic Lymphocytic Leukemia (ICGC-CLL Genome Project), and project PM15/00007, which is part of Plan Nacional de I+D+I and are co-financed by FEDER. NG is a recipient of a predoctoral fellowship from Agaur and EC is an Academia Researcher of the "Institució Catalana de Recerca i Estudis Avançats" (ICREA) of the Generalitat de Catalunya.Giménez, N., Martínez-Trillos, A., Montraveta, A., Lopez-Guerra, M., Rosich, L., Nadeu, F., Valero, J.G., Aymerich, M., Magnano, L., Rozman, M., Matutes, E., Delgado, J., Baumann, T., Gine, E., González, M., Alcoceba, M., Terol, M.J., Navarro, B., Colado, E., Payer, A.R., Puente, X.S., López-Otín, C., Lopez-Guillermo, A., Campo, E., Colomer, D., Villamor, N

SenSem: sentidos verbales, semántica oracional y anotación de corpus

En este artículo presentamos el desarrollo del proyecto SenSem (BFF2003-06456), que tiene como objetivo describir y representar el comportamiento léxico, sintáctico y semántico de los verbos del español. En el desarrollo de este proyecto se están construyendo dos recursos: un corpus de oraciones asociadas a su interpretación sintáctico-semántica y un léxico donde cada sentido verbal se asocia a un conjunto de ejemplos anotados del corpus

Estudio experimental sobre la influencia de la temperatura ambiental en la resistencia del hormigón preparado. Parte 2: implementación industrial

This paper is the second part of an experimental study about the effect of environmental temperature on the concrete performance, from an industrial perspective. An earlier article on its effect on aggregate, paste, mortar and concrete workability and mechanical properties reported that high temperature had a clearly adverse impact on strength, which can generally be offset with overdoses of both cement and water to maintain the original water/cement ratio. In this second part of the paper the basis of a methodological formulation is presented, with the purpose of carry out the optimization of the overdosage of cement in concrete in hot climates, in order to be industrially implemented in ready mix concrete plants. This proposal has been successfully applied in some ready mix concrete plants of the company Promotora Mediterránea 2, S.A. (PROMSA), considering that the cement content (overdosage) in concrete can be optimized without any adverse effect in its performance, reason why it is possible to reduce the production costs of concrete without reducing its quality.El presente artículo constituye la segunda parte de un estudio experimental sobre la influencia de la temperatura ambiental sobre las prestaciones del hormigón, desde una perspectiva industrial. En la primera, se estudió el efecto sobre las propiedades de trabajabilidad y mecánicas, en áridos, pasta, mortero y hormigones, detectando un claro efecto negativo de la temperatura elevada sobre la resistencia, que se suele solucionarcon una sobredosificación en cemento y agua, para mantenerla relación agua/cemento original.En esta segunda parte del artículo, se presentan las bases de una formulación metodológica para llevar a cabo la optimización de la sobredosificación de cemento en el hormigón en climas cálidos, para ser implementada industrialmente en plantas de hormigón preparado. Dicha propuesta se ha aplicado con éxito a escala industrial en plantas de producción de hormigón preparado de Promotora Mediterránea 2, S.A. (PROMSA), considerando que la sobredosificación de cemento en el hormigón puede ser optimizado sin causar detrimentos en las prestaciones del mismo, lo que permite reducir costes de producción sin castigar la calidad del producto

Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment

Background/aims: Changes in gene expression profiles among individuals with inflammatory bowel diseases (IBDs) could potentially influence the responsiveness to anti-TNF treatment. The aim of this study was to identify genes that could serve as predictors of early response to anti-TNF therapies in pediatric IBD patients prior to the initiation of treatment. Methods: We conducted a prospective, longitudinal, and multicenter study, enrolling 24 pediatric IBD patients aged less than 18 years who were initiating treatment with either infliximab or adalimumab. RNA-seq from blood samples was analyzed using the DESeq2 library by comparing responders and non-responders to anti-TNF drugs. Results: Bioinformatic analyses unveiled 102 differentially expressed genes, with 99 genes exhibiting higher expression in responders compared to non-responders prior to the initiation of anti-TNF therapy. Functional enrichment analyses highlighted defense response to Gram-negative bacteria (FDR = 2.3 ×10-7) as the most significant biological processes, and hemoglobin binding (FDR = 0.002), as the most significant molecular function. Gene Set Enrichment Analysis (GSEA) revealed notable enrichment in transcriptional misregulation in cancer (FDR = 0.016). Notably, 13 genes (CEACAM8, CEACAM6, CILP2, COL17A1, OLFM4, INHBA, LCN2, LTF, MMP8, DEFA4, PRTN3, AZU1, and ELANE) were selected for validation, and a consistent trend of increased expression in responders prior to drug administration was observed for most of these genes, with findings for 4 of them being statistically significant (CEACAM8, LCN2, LTF2, and PRTN3). Conclusions: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs

SenSem: sentidos verbales, semántica oracional y anotación de corpus

En este artículo presentamos el desarrollo del proyecto SenSem (BFF2003-06456), que tiene como objetivo describir y representar el comportamiento léxico, sintáctico y semántico de los verbos del español. En el desarrollo de este proyecto se están construyendo dos recursos: un corpus de oraciones asociadas a su interpretación sintáctico-semántica y un léxico donde cada sentido verbal se asocia a un conjunto de ejemplos anotados del corpus

New synthetic AICAR derivatives with enhanced AMPK and ACC activation

5-Aminoimidazole-4-carboxamide riboside (AICAR) has an important role in the regulation of the cellular metabolism showing a broad spectrum of therapeutic activities against different metabolic processes. Due to these proven AICAR properties, we have designed, synthesized and tested the biological activity of two ribose-modified AICAR derivatives, named A3 and A4, in comparison to native AICAR and its 5'-phosphorylated counterpart ZMP. Our findings have shown that A3 and A4 derivatives induce the phosphorylation of 5'-AMP activated protein kinase α (AMPKα), which leads to the inhibition of acetyl-CoA carboxylase (ACC), and down-regulate the activity of the extracellular signal-regulated kinases (ERK1/2). Cytotoxicity tests demonstrated that A3 and A4 do not significantly reduce cell viability up to 24 h. Taken together our results indicate that A3 and A4 have a comparable activity to AICAR and ZMP at 0.5 and 1 mM suggesting their potential use in future pharmacological strategies relating to metabolic diseases

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

Abstract Introduction: BTK is involved in B-cell receptor (BCR) signal transduction and is an established target for the treatment of chronic lymphocytic leukemia (CLL) (Byrd, NEJM, 2013). ACP-196 is a novel, potent second generation BTK inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK. IC50determinations on nine kinases with a cysteine in the same position as BTK showed ACP-196 to be more selective than the first-in-class BTK inhibitor, ibrutinib (Covey, AACR, 2015). We present data evaluating the anti-tumor effects of ACP-196 in established murine models of CLL. Methods: Two distinct murine models were used for these studies. In the TCL1 adoptive transfer model, leukemic cells from Eμ-TCL1 transgenic mice were transplanted into C57BL/6 mice, resulting in a CD5+/CD19+ leukemia with peripheral blood, spleen and nodal involvement. ACP-196 treatment in drinking water (0.16 mg/mL) commenced when recipient mice had &gt; 10% CD5+/CD19+ leukocytes in the peripheral blood. Mice were followed for survival. Separate cohorts were sacrificed for pharmacodynamic analyses after 1 and 4 weeks of treatment. In the second model, NSG mice received primary human CLL cells. The xenografted human CLL cells have comparable tumor biology (including active BCR signaling) to activated human lymph node resident CLL cells (Herman, Leukemia, 2013). PBMCs harvested from CLL patients were adoptively transferred at 1 x 108 cells per mouse. ACP-196 was initiated on day -1 (at the time of busulfan priming) at multiple doses ranging from 0.006 to 0.3 mg/mL in drinking water. Results: In the TCL1 model, treatment with ACP-196 showed &gt; 90% BTK occupancy of BTK after 1 and 4 weeks of therapy. ACP-196 inhibited BCR signaling as shown by decreased autophosphorylation of BTK and reduction in surface expression of the BCR activation markers CD86 and CD69. After 1 week of ACP-196 inhibited BCR signaling as shown by a 6-fold reduction of autophosphorylation of BTK in the presence of anti-IgM, and surface expression of the BCR activation markers CD69 and CD86 were decreased by 47% and 57% respectively. Inhibition of BTK and downstream BCR activation was maintained through at least day 28 of treatment. Most notably, ACP-196 treatment resulted in a significant increase in survival compared with mice receiving vehicle (median 81 vs 59 days, respectively; P =0.02). In the NSG xenograft model, ACP-196 at the times examined did not cause a significant treatment-induced lymphocytosis in the patients evaluated (n=6). After 4 weeks of treatment with ACP-196, the NSG mice were sacrificed, and BCR signaling activity and tumor burden in the spleen were evaluated. ACP-196 treatment showed decreases in phosphorylation of PLCγ2 and ERK (P &lt;0.02) as expected with BTK inhibition. Additionally, a significant reduction was observed in the percentage of proliferating cells in mice treated with ACP-196 compared to vehicle control (as determined by Ki67 staining; median 18% (Intraquartile Range (IQR): 13-38) and 6% (IQR: 2-15), respectively, P =0.02). Lastly, a significant reduction in total tumor burden in the spleen was observed in the mice treated with ACP-196 (median reduction of 33%) compared with the vehicle treated mice (P =0.04). Conclusions: ACP-196 is a potent inhibitor of BTK as measured by inhibition of BCR activity, reduced tumor proliferation and increased survival. Overall, ACP-196 showed statistically significant efficacy in two murine models of CLL and is currently in Phase 3 trials for treatment-naive (ClinicalTrials.gov NCT0247568) and previously treated high-risk CLL (ClinicalTrials.gov NCT02477696). This work was supported by the Intramural Research Program of NHLBI, NIH, R01CA197870, K23 CA178183-02, and Acerta Pharma. Disclosures Gulrajani: Acerta Pharma: Employment. Krantz:Acerta Pharma: Employment. Covey:Acerta Pharma BV: Employment, Equity Ownership, Patents &amp; Royalties. Lannutti:Acerta Pharma: Employment. Izumi:Acerta Pharma: Employment, Equity Ownership, Patents &amp; Royalties. Ulrich:Acerta Pharma: Employment. Byrd:Acerta Pharma BV: Research Funding. Wiestner:Pharmacyclics: Research Funding. Johnson:Acerta Pharma: Research Funding. </jats:sec